77 related articles for article (PubMed ID: 24497344)
1. Neoatherosclerosis as reason for stent failures beyond 5 years after drug-eluting stent implantation.
Taniwaki M; Windecker S; Räber L
Eur Heart J; 2014 Aug; 35(29):1980. PubMed ID: 24497344
[No Abstract] [Full Text] [Related]
2. Drug-eluting stents: do the risks really outweigh the benefits?
Austin D; Pell JP; Oldroyd KG
Heart; 2008 Feb; 94(2):127-8. PubMed ID: 18195113
[No Abstract] [Full Text] [Related]
3. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of drug-eluting stents when inserted for on- and off-label indications.
Qasim A; Cosgrave J; Latib A; Colombo A
Am J Cardiol; 2007 Dec; 100(11):1619-24. PubMed ID: 18036358
[TBL] [Abstract][Full Text] [Related]
5. Neoatherosclerosis, plaque rupture and very late stent thrombosis of a first generation drug eluting stent treated with aspiration thrombectomy and newer generation drug eluting stent implantation.
Mustafa A; Daghem S; Farooq V; Fath-Ordoubadi F; Clarke B
Int J Cardiol; 2015 Dec; 201():648-9. PubMed ID: 26344489
[No Abstract] [Full Text] [Related]
6. Neoatherosclerosis as the cause of very late bare-metal stent restenosis: optical coherence tomography evaluation.
Ruiz-García J; Jiménez-Valero S; Galeote G; Sánchez-Recalde A; García-Blas S; Moreno R
Rev Esp Cardiol (Engl Ed); 2013 May; 66(5):403-5. PubMed ID: 24775826
[No Abstract] [Full Text] [Related]
7. Degradable, drug-eluting stents: a new frontier for the treatment of coronary artery disease.
Kohn J; Zeltinger J
Expert Rev Med Devices; 2005 Nov; 2(6):667-71. PubMed ID: 16293093
[TBL] [Abstract][Full Text] [Related]
8. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
[TBL] [Abstract][Full Text] [Related]
9. Two-year follow-up of the Genous™ endothelial progenitor cell capturing stent versus the Taxus Liberté stent in patients with de novo coronary artery lesions with a high-risk of restenosis: a randomized, single-center, pilot study.
Beijk MA; Klomp M; van Geloven N; Koch KT; Henriques JP; Baan J; Vis MM; Tijssen JG; Piek JJ; de Winter RJ
Catheter Cardiovasc Interv; 2011 Aug; 78(2):189-95. PubMed ID: 21542109
[TBL] [Abstract][Full Text] [Related]
10. Bilateral coronary ostial stenosis with bilateral renal ostial stenosis in cardiovascular syphilis: de novo percutaneous coronary intervention and in-stent restenosis.
Kharge J; Bharatha A; Raghu TR; Manjunath CN
Eur Heart J; 2013 Sep; 34(34):2682. PubMed ID: 23386712
[No Abstract] [Full Text] [Related]
11. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
12. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
[TBL] [Abstract][Full Text] [Related]
13. Outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program.
Brilakis ES; Lasala JM; Cox DA; Berger PB; Bowman TS; Starzyk RM; Dawkins KD
JACC Cardiovasc Interv; 2010 Jul; 3(7):742-50. PubMed ID: 20650436
[TBL] [Abstract][Full Text] [Related]
14. Increased thin-cap neoatheroma and periprocedural myocardial infarction in drug-eluting stent restenosis: multimodality intravascular imaging of drug-eluting and bare-metal stents.
Ali ZA; Roleder T; Narula J; Mohanty BD; Baber U; Kovacic JC; Mintz GS; Otsuka F; Pan S; Virmani R; Sharma SK; Moreno P; Kini AS
Circ Cardiovasc Interv; 2013 Oct; 6(5):507-17. PubMed ID: 24065447
[TBL] [Abstract][Full Text] [Related]
15. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
[TBL] [Abstract][Full Text] [Related]
16. Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) group.
Brodie BR; Wilson H; Stuckey T; Nussbaum M; Laurent S; Bradshaw B; Humphrey A; Metzger C; Hermiller J; Krainin F; Juk S; Cheek B; Duffy P; Simonton CA;
JACC Cardiovasc Interv; 2009 Nov; 2(11):1105-12. PubMed ID: 19926052
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of drug-eluting stents versus bare-metal stents in saphenous vein graft disease: results from the Prairie "Real World" Stent Registry.
Goswami NJ; Gaffigan M; Berrio G; Plessa AL; Pfeiffer AM; Markwell SJ; Mishkel GJ
Catheter Cardiovasc Interv; 2010 Jan; 75(1):93-100. PubMed ID: 19787803
[TBL] [Abstract][Full Text] [Related]
18. Extremely late drug-eluting stent thrombosis related to uncovered struts: the phantom menace.
Spagnoli V; Veugeois A; Caussin C; Amabile N
Eur Heart J; 2013 Aug; 34(31):2428. PubMed ID: 23821398
[No Abstract] [Full Text] [Related]
19. Coexistent in-stent restenosis, late incomplete stent apposition and mural thrombus in a zotarolimus-eluting stent.
Zhang F; Qian J; Ge J
J Invasive Cardiol; 2008 Aug; 20(8):423-5. PubMed ID: 18688068
[TBL] [Abstract][Full Text] [Related]
20. 3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial.
Holmes DR; Teirstein PS; Satler L; Sketch MH; Popma JJ; Mauri L; Wang HP; Schleckser PA; Cohen SA;
JACC Cardiovasc Interv; 2008 Aug; 1(4):439-48. PubMed ID: 19463342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
